Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEA-pulsed dendritic cells
- Development stage
- Phase 2
- Lead developer
- National Taiwan University Hospital
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal, Subcutaneous
01
Overview
CEA-pulsed dendritic cells (National Taiwan University Hospital) is an investigational autologous cellular immunotherapy developed for the treatment of advanced or metastatic colorectal cancer. The therapy involves harvesting a patient's own mononuclear cells and differentiating them into dendritic cells, which are then pulsed ex vivo with the whole carcinoembryonic antigen (CEA) protein. These antigen-loaded dendritic cells function as potent antigen-presenting cells designed to stimulate a targeted T-cell mediated immune response against CEA-expressing tumor cells. In clinical trial protocols, the dendritic cells are mixed with tetanus toxoid as an adjuvant to enhance the immune response and are typically followed by low-dose subcutaneous interleukin-2 (IL-2) to promote the growth and activity of the induced T cells.
- Other names
- CEA pulsed dendritic cells-National Taiwan University Hospital-colorectal cancerCEA-pulsed dendritic cell vaccineCEA-pulsed DC vaccineAutologous CEA-pulsed dendritic cells
02
Targets
Carcinoembryonic antigen (CEA) peptide-HLA-A2/A24 complex
Beyond the preview
Go deeper on CEA-pulsed dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEA-pulsed dendritic cells.